

Appendix 1 (as supplied by the authors): Supplemental material

Supplemental Table S1: Top 10 chemicals by total drug program spending by high cost category and by jurisdiction, fiscal year 2016

Note: Biologics (not including insulin or LMWH) highlighted in Blue. Antivirals are highlighted in Yellow.

		Very high drug-cost Beneficiaries (Top 1%)		High drug-cost Beneficiaries (Top 5%)		Other beneficiaries	
Jurisdiction	Rank	Drug Name	Total program spending	Drug Name	Total program spending	Drug Name	Total program spending
Alberta	1	Infliximab	\$ 64,867,932	Adalimumab	\$ 15,203,734	Salmeterol/Fluticasone	\$ 14,831,765
	2	Adalimumab	\$ 22,541,668	Glatiramer	\$ 8,771,051	Atorvastatin	\$ 12,238,077
	3	Sofosbuvir/Ledipasvir	\$ 18,438,149	Ranibizumab	\$ 8,172,466	Perindopril	\$ 10,760,204
	4	Etanercept	\$ 13,613,780	Infliximab	\$ 7,673,371	Pantoprazole	\$ 10,565,809
	5	Fingolimod	\$ 7,766,826	Etanercept	\$ 7,322,786	Formoterol/Budesonide	\$ 10,260,184
	6	Dimethyl fumarate	\$ 5,239,637	Insulin glargine	\$ 5,471,808	Rivaroxaban	\$ 9,512,546
	7	Eculizumab	\$ 4,867,085	Ustekinumab	\$ 5,318,795	Rosuvastatin	\$ 9,416,492
	8	Octreotide	\$ 4,366,391	Darbepoetin alfa	\$ 4,902,197	Tiotropium	\$ 8,710,675
	9	Interferon beta-1a	\$ 4,179,173	Oxycodone	\$ 4,591,761	Insulin glargine	\$ 7,982,133
	10	Ustekinumab	\$ 3,942,333	Tinzaparin	\$ 3,725,097	Amlodipine	\$ 7,829,082
BC	1	Infliximab	\$ 78,004,144	Adalimumab	\$ 34,992,444	Methadone	\$ 18,223,015
	2	Sofosbuvir and ledipasvir	\$ 77,711,332	Etanercept	\$ 21,280,993	Nicotine	\$ 14,368,720
	3	Adalimumab	\$ 28,897,862	Paliperidone	\$ 16,557,128	Atorvastatin	\$ 11,565,450
	4	Sofosbuvir	\$ 19,268,081	Infliximab	\$ 10,651,648	Quetiapine	\$ 10,465,102
	5	Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir	\$ 16,854,455	Clozapine	\$ 9,562,226	Salmeterol/Fluticasone	\$ 10,347,632
	6	Alfa1 antitrypsin	\$ 7,253,536	Methadone	\$ 8,171,709	Ramipril	\$ 8,085,614
	7	Fingolimod	\$ 6,399,483	Aripiprazole	\$ 8,065,912	Gabapentin	\$ 8,068,948
	8	Etanercept	\$ 5,576,629	Abatacept	\$ 6,409,482	Insulin glargine	\$ 8,062,263

	9	Dimethyl fumarate	\$ 4,405,563	Quetiapine	\$ 5,525,898	Aripiprazole	\$ 7,965,701
	10	Ustekinumab	\$ 3,355,662	Golimumab	\$ 5,238,164	Amlodipine	\$ 6,980,233
Manitoba	1	Infliximab	\$ 29,708,571	Adalimumab	\$ 12,666,070	Salmeterol/Fluticasone	\$ 4,723,815
	2	Sofosbuvir /Ledipasvir	\$ 8,773,436	Etanercept	\$ 9,221,641	Atorvastatin	\$ 2,666,029
	3	Lenalidomide	\$ 7,827,696	Infliximab	\$ 6,328,948	Aripiprazole	\$ 2,323,571
	4	Adalimumab	\$ 7,001,596	Interferon beta-1a	\$ 3,978,582	Hydromorphone	\$ 2,081,694
	5	Etanercept	\$ 3,833,907	Glatiramer acetate	\$ 2,602,596	Omeprazole	\$ 2,041,208
	6	Sofosbuvir	\$ 3,599,508	Ustekinumab	\$ 1,855,149	Gabapentin	\$ 1,991,915
	7	Alfa1 antitrypsin	\$ 2,590,337	Tenofovir/Emtricitabine	\$ 1,820,047	Methylphenidate	\$ 1,832,170
	8	Octreotide	\$ 1,662,581	Dimethyl fumarate	\$ 1,773,657	Clozapine	\$ 1,801,696
	9	Alglucosidase alfa	**	Golimumab	\$ 1,608,363	Quetiapine	\$ 1,767,142
	10	Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir	\$ 1,168,231	Darunavir	\$ 1,602,081	Risperidone	\$ 1,696,644
New Brunswick	1	Infliximab	\$ 7,614,736	Ranibizumab	\$ 2,881,004	Salmeterol/Fluticasone	\$ 3,804,852
	2	Lenalidomide	\$ 4,805,559	Methadone	\$ 2,436,610	Perindopril	\$ 3,690,595
	3	Adalimumab	\$ 3,539,920	Aflibercept	\$ 2,149,400	Methadone	\$ 3,597,739
	4	Etanercept	\$ 2,086,924	Adalimumab	\$ 2,104,495	Pantoprazole	\$ 2,993,426
	5	Sofosbuvir/Ledipasvir	\$ 1,744,353	Paliperidone	\$ 2,103,991	Atorvastatin	\$ 2,416,560
	6	Ustekinumab	\$ 1,180,724	Hydromorphone	\$ 1,336,460	Nifedipine	\$ 2,396,405
	7	Teriflunomide	\$ 1,123,646	Risperidone	\$ 1,264,379	Rosuvastatin	\$ 2,371,423
	8	Dimethyl fumarate	\$ 1,122,056	Infliximab	\$ 1,247,366	Fluticasone	\$ 2,134,415
	9	Interferon beta-1a	\$ 1,009,154	Etanercept	\$ 1,239,067	Rivaroxaban	\$ 1,893,174
	10	Ranibizumab	\$ 843,777	Clozapine	\$ 975,819	Perindopril/Diuretics	\$ 1,808,922
Newfoundland	1	Infliximab	\$ 4,245,402	Methadone	\$ 2,929,381	Nifedipine	\$ 2,640,961
	2	Lenalidomide	\$ 3,417,974	Ranibizumab	\$ 1,641,543	Rosuvastatin	\$ 2,294,220
	3	Adalimumab	\$ 3,320,198	Insulin (human)	\$ 846,398	Rabeprazole	\$ 2,019,865
	4	Sofosbuvir/Ledipasvir	\$ 2,488,984	Adalimumab	\$ 833,129	Fluticasone	\$ 1,939,230
	5	Ustekinumab	\$ 1,290,300	Insulin (human)	\$ 783,089	Atorvastatin	\$ 1,670,545
	6	Golimumab	\$ 1,068,247	Darbepoetin alfa	\$ 599,397	Methadone	\$ 1,551,484
	7	Imiglucerase	**	Salmeterol/Fluticasone	\$ 451,759	Perindopril	\$ 1,486,857

	8	Dimethyl fumarate	\$ 929,877	Clozapine	\$ 402,894	Metoprolol	\$ 1,317,710
	9	Etanercept	\$ 905,340	Paliperidone	\$ 382,815	Salmeterol/Fluticasone	\$ 1,315,805
	10	Interferon beta-1a	\$ 769,915	Morphine	\$ 369,167	Omeprazole	\$ 1,202,767
Nova Scotia	1	Infliximab	\$ 8,510,238	Adalimumab	\$ 1,508,474	Rosuvastatin	\$ 3,274,532
	2	Adalimumab	\$ 6,151,155	Insulin glargine	\$ 1,044,312	Atorvastatin	\$ 2,941,950
	3	Lenalidomide	\$ 4,728,894	Hydromorphone	\$ 1,004,208	Perindopril	\$ 2,782,994
	4	Etanercept	\$ 3,856,445	Insulin (human)	\$ 979,550	Rabeprazole	\$ 2,433,663
	5	Ivacaftor	\$ 1,718,320	Salmeterol/Fluticasone	\$ 919,444	Levothyroxine sodium	\$ 2,140,084
	6	Golimumab	\$ 1,241,652	Dalteparin	\$ 753,367	Nifedipine	\$ 2,110,545
	7	Ustekinumab	\$ 1,074,379	Etanercept	\$ 724,671	Salmeterol/Fluticasone	\$ 2,105,252
	8	Sofosbuvir/Ledipasvir	\$ 986,105	Insulin detemir	\$ 635,095	Insulin (human)	\$ 1,974,249
	9	Octreotide	\$ 976,124	Insulin aspart	\$ 633,899	Amlodipine	\$ 1,876,032
	10	Abatacept	\$ 833,096	Infliximab	\$ 615,735	Omeprazole	\$ 1,806,201
Ontario	1	Sofosbuvir/Ledipasvir	\$ 148,382,350	Ranibizumab	\$ 127,278,505	Metformin and sitagliptin	\$ 79,071,410
	2	Infliximab	\$ 102,676,705	Aflibercept	\$ 112,664,676	Atorvastatin	\$ 72,434,758
	3	Lenalidomide	\$ 96,914,294	Paliperidone	\$ 37,426,387	Sitagliptin	\$ 70,017,206
	4	Ranibizumab	\$ 66,839,510	Insulin glargine	\$ 25,713,848	Salmeterol/Fluticasone	\$ 69,070,354
	5	Aflibercept	\$ 56,911,069	Hydromorphone	\$ 22,882,175	Perindopril	\$ 65,554,954
	6	Adalimumab	\$ 50,579,837	Aripiprazole	\$ 20,789,393	Apixaban	\$ 59,605,420
	7	Etanercept	\$ 43,524,508	Adalimumab	\$ 19,488,982	Rosuvastatin	\$ 59,534,671
	8	Sofosbuvir	\$ 43,520,384	Lamivudine/Abacavir/Dolutegravir	\$ 18,886,292	Rivaroxaban	\$ 53,077,762
	9	Eculizumab	\$ 31,107,836	Tenofovir	\$ 17,137,188	Insulin glargine	\$ 50,378,061
	10	Octreotide	\$ 23,355,851	Risperidone	\$ 15,792,857	Methadone	\$ 49,284,275
PEI	1	Infliximab	\$ 1,471,212	Methadone	\$ 642,682	Pantoprazole	\$ 552,717
	2	Adalimumab	\$ 1,440,688	Insulin (human)	\$ 159,751	Methadone	\$ 464,136
	3	Lenalidomide	\$ 814,157	Pantoprazole	\$ 141,566	Atorvastatin	\$ 364,888
	4	Etanercept	\$ 449,238	Salmeterol/Fluticasone	\$ 124,469	Rosuvastatin	\$ 335,442
	5	Pirfenidone	\$ 287,202	Clozapine	\$ 123,870	Perindopril	\$ 301,234
	6	Aflibercept	\$ 262,070	Adalimumab	\$ 122,548	Amlodipine	\$ 264,573
	7	Risperidone	\$ 237,664	Insulin lispro	\$ 111,587	Insulin (human)	\$ 230,631

	8	Golimumab	\$ 226,509	Olanzapine	\$ 111,147	Fluticasone	\$ 213,218
	9	Interferon beta-1a	\$ 222,685	Fluticasone	\$ 107,413	Omeprazole	\$ 209,668
	10	Fingolimod	\$ 219,460	Hydromorphone	\$ 101,677	Nifedipine	\$ 194,951
Saskatchewan	1	Infliximab	\$ 29,224,199	Adalimumab	\$ 4,341,960	Methylphenidate	\$ 4,134,652
	2	Adalimumab	\$ 13,904,222	Etanercept	\$ 3,251,959	Insulin glargine	\$ 3,565,614
	3	Sofosbuvir/Ledipasvir	\$ 8,070,050	Hydromorphone	\$ 3,076,061	Salmeterol/Fluticasone	\$ 2,986,275
	4	Etanercept	\$ 5,352,192	Insulin glargine	\$ 2,716,952	Perindopril	\$ 2,953,658
	5	Dimethyl fumarate	\$ 3,687,514	Infliximab	\$ 2,669,912	Hydromorphone	\$ 2,707,466
	6	Sofosbuvir	\$ 2,467,151	Glatiramer	\$ 2,542,614	Rivaroxaban	\$ 2,616,595
	7	Interferon beta-1a	\$ 1,955,792	Paliperidone	\$ 2,215,723	Nifedipine	\$ 2,484,144
	8	Ustekinumab	\$ 1,840,246	Clozapine	\$ 1,966,654	Atorvastatin	\$ 2,428,239
	9	Golimumab	\$ 1,839,197	Golimumab	\$ 1,900,253	Rosuvastatin	\$ 2,036,727
	10	Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir	\$ 1,012,192	Erythropoietin	\$ 1,662,673	Tiotropium	\$ 2,032,495

Supplemental Table S2: Top 10 chemicals by rate of use, by high cost category and by jurisdiction, fiscal year 2016

Note: Biologics (not including insulin or LMWH) highlighted in Blue. Antivirals are highlighted in Yellow.

		Very high drug-cost Beneficiaries (Top 1%)		High drug-cost Beneficiaries (Top 5%)		Other beneficiaries	
Jurisdiction	Rank	Drug Name	Number of Users (n)	Drug Name	Number of Users (n)	Drug Name	Number of Users (n)
Alberta	1	Infliximab	1,785	Rosuvastatin	101,728	Levothyroxine	115,386
	2	Pantoprazole	1,206	Atorvastatin	96,282	Pantoprazole	114,298
	3	Methotrexate	1,137	Metformin	78,404	Rosuvastatin	101,728
	4	Adalimumab	1,118	Amlodipine	76,953	Atorvastatin	96,282
	5	Folic acid	948	Amoxicillin	70,730	Metformin	78,404
	6	Codeine/APAP	858	Zopiclone	70,544	Amlodipine	76,953
	7	Zopiclone	820	Diclofenac	68,515	Amoxicillin	70,730
	8	Prednisone	782	Codeine /APAP	67,620	Zopiclone	70,544
	9	Levothyroxine	733	Rosuvastatin	101,728	Diclofenac	68,515
	10	Amoxicillin	729	Atorvastatin	96,282	Codeine /APAP	67,620
BC	1	Infliximab	2,323	Salbutamol	6,186	Levothyroxine	87,178
	2	Codeine /APAP	1,287	Codeine /APAP	5,561	Ramipril	86,533
	3	Sofosbuvir /ledipasvir	1,278	Gabapentin	5,465	Atorvastatin	86,055
	4	Adalimumab	1,157	Quetiapine	5,159	Codeine /APAP	83,408
	5	Salbutamol	1,126	Lorazepam	4,744	Amoxicillin	79,299

	6	Prednisone	1,065	Atorvastatin	4,215	Salbutamol	78,086
	7	Methotrexate	876	Metformin	4,073	Metformin	74,771
	8	Amoxicillin	868	Pantoprazole	4,023	Nicotine	70,813
	9	Lorazepam	759	Levothyroxine	4,013	Rosuvastatin	66,972
	10	Gabapentin	751	Ramipril	4,008	Amlodipine	64,547
	1	Infliximab	506	Codeine /APAP	1,218	Salbutamol	21,055
	2	Codeine /APAP	309	Salbutamol	1,170	Amoxicillin	19,180
	3	Hydrocortisone	258	Levothyroxine sodium	888	Codeine /APAP	18,777
	4	Zopiclone	213	Gabapentin	881	Levothyroxine	18,628
	5	Salbutamol	207	Zopiclone	852	Atorvastatin	17,679
	6	Prednisone	203	Prednisone	811	Metformin	17,020
	7	Adalimumab	188	Metformin	810	Metoprolol	15,737
	8	Amoxicillin	185	Atorvastatin	779	Furosemide	14,472
	9	Omeprazole	176	Omeprazole	768	APAP	13,787
Manitoba	10	Azithromycin	168	Adalimumab	748	Omeprazole	13,199
	1	Pantoprazole	433	Pantoprazole	1,968	Pantoprazole	33,131
	2	Salbutamol	290	Salbutamol	1,637	Rosuvastatin	23,935
	3	Zopiclone	284	Zopiclone	1,309	Salbutamol	23,158
	4	Infliximab	239	Lorazepam	986	Levothyroxine	21,228
	5	Gabapentin	206	Rosuvastatin	973	Atorvastatin	17,287
New Brunswick	6	Prednisone	206	Furosemide	936	Metformin	16,745

	7	Lorazepam	198	Metformin	934	Zopiclone	16,123
	8	Rosuvastatin	192	Prednisone	909	Lorazepam	15,156
	9	Adalimumab	175	Levothyroxine	897	Amoxicillin	13,746
	10	Levothyroxine	154	Gabapentin	880	Metoprolol	12,101
Newfoundland	1	Rabeprazole	306	Salbutamol	1,583	Amoxicillin	21,174
	2	Salbutamol	236	Rabeprazole	1,562	Rosuvastatin	20,799
	3	Prednisone	229	Rosuvastatin	1,155	Rabeprazole	20,394
	4	Zopiclone	195	Zopiclone	1,146	Salbutamol	19,368
	5	Adalimumab	184	Insulin (human)	1,117	Metoprolol	14,493
	6	Rosuvastatin	180	Furosemide	1,034	Metformin	13,366
	7	Amoxicillin	178	Amoxicillin	973	Lorazepam	12,418
	8	Lorazepam	164	Metformin	967	Atorvastatin	11,368
	9	Ciprofloxacin	161	Lorazepam	956	Hydrochlorothiazide	11,139
	10	Infliximab	157	Insulin (human)	929	Levothyroxine sodium	11,026
Nova Scotia	1	Adalimumab	326	Salbutamol	2,132	Rosuvastatin	30,964
	2	Infliximab	309	Furosemide	1,946	Levothyroxine	28,840
	3	Rabeprazole	284	Rabeprazole	1,680	Rabeprazole	23,155
	4	Methotrexate	262	Metformin	1,669	Atorvastatin	21,004
	5	Levothyroxine	229	Rosuvastatin	1,629	Metoprolol	20,097
	6	Salbutamol	222	Levothyroxine	1,625	Salbutamol	19,520
	7	Prednisone	219	Metoprolol	1,390	Metformin	19,248

	8	Rosuvastatin	217	Insulin (human)	1,345	Hydrochlorothiazide	17,138
	9	Etanercept	197	Prednisone	1,321	Amlodipine	16,569
	10	Folic acid	179	Atorvastatin	1,287	Amoxicillin	14,762
Ontario	1	Pantoprazole	7,083	Pantoprazole	37,252	Rosuvastatin	604,402
	2	Salbutamol	5,977	Salbutamol	33,686	Atorvastatin	506,390
	3	Rosuvastatin	5,464	Rosuvastatin	30,160	Pantoprazole	486,193
	4	Amoxicillin	4,608	Atorvastatin	28,181	Amoxicillin	457,544
	5	Amlodipine	4,575	Metformin	27,005	Amlodipine	422,938
	6	Atorvastatin	4,458	Furosemide	25,900	Salbutamol	402,057
	7	Codeine /APAP	4,107	Amlodipine	25,040	Levothyroxine	391,981
	8	Prednisone	4,057	Levothyroxine	21,504	Metformin	348,436
	9	Levothyroxine	3,843	Amoxicillin	21,316	Codeine /APAP	323,008
	10	Metformin	3,756	Hydromorphone	20,883	Ramipril	273,744
PEI	1	Pantoprazole	96	Pantoprazole	585	Rosuvastatin	6,369
	2	Adalimumab	90	Salbutamol	573	Levothyroxine	6,008
	3	Salbutamol	89	Levothyroxine	382	Metformin	6,001
	4	Prednisone	56	Metformin	353	Pantoprazole	5,791
	5	Infliximab	55	Furosemide	346	Amoxicillin	5,498
	6	Levothyroxine	52	Rosuvastatin	326	Amlodipine	4,487
	7	Amoxicillin	50	Amoxicillin	322	Atorvastatin	4,442
	8	Metformin	49	Ipratropium	309	Ramipril	4,010

	9	Cefalexin	49	Insulin (human)	305	Salbutamol	3,869
	10	Rosuvastatin	47	Prednisone	287	Metoprolol	3,783
Saskatchewan	1	Infliximab	866	Furosemide	2,942	Amoxicillin	41,488
	2	Folic acid	550	Salbutamol	2,838	Rosuvastatin	28,126
	3	Adalimumab	537	Metformin	2,742	Cefalexin	26,300
	4	Prednisone	506	Pantoprazole	2,639	Atorvastatin	24,905
	5	Methotrexate	476	Insulin glargine	2,508	Levothyroxine	24,380
	6	Pantoprazole	443	Hydromorphone	2,308	Metformin	24,343
	7	Salbutamol	409	Prednisone	2,233	Salbutamol	23,633
	8	Amoxicillin	401	Levothyroxine	2,089	Pantoprazole	22,440
	9	Hydromorphone	378	Rosuvastatin	2,036	Azithromycin	20,390
	10	Cefalexin	365	Atorvastatin	1,991	Amlodipine	19,481

Supplemental Table S3: Proportion of total program spending (TPS) and total program spending by high drug-cost beneficiaries group including Cancer, fiscal year 2016

Jurisdiction	Top 1%		Top 5%		Top 10%		Overall
	Total Program Spending	Proportion of TPS	Total Program Spending	Proportion of TPS	Total Program Spending	Proportion of TPS	Total Program Spending
	(\$ Million)	(%)	(\$ Million)	(%)	(\$ Million)	(%)	(\$ Million)
BC	\$ 297.8	27.4	\$ 586.6	54.0	\$ 731.9	67.3	\$ 1,087.2
AB	\$ 189.3	24.5	\$ 363.5	47.0	\$ 450.7	58.3	\$ 773.3
SK	\$ 89.7	28.3	\$ 175.5	55.4	\$ 218.0	68.8	\$ 316.7
MB	\$ 85.5	26.6	\$ 174.7	54.5	\$ 215.3	67.1	\$ 320.8
ON	\$ 1,107.5	21.6	\$ 2,242.6	43.7	\$ 2,915.8	56.9	\$ 5,126.3
NB	\$ 44.2	21.0	\$ 93.5	44.3	\$ 119.7	56.8	\$ 210.9
PE	\$ 7.6	29.2	\$ 13.7	52.6	\$ 17.2	65.9	\$ 26.0
NS	\$ 42.2	22.6	\$ 76.3	40.8	\$ 99.1	53.0	\$ 187.0
NL	\$ 29.1	21.3	\$ 56.0	41.0	\$ 74.1	54.2	\$ 136.8

Supplemental Table S4: Drug utilization among the top 1% of beneficiaries group, fiscal year 2016


Jurisdiction	Top 1%		
	Number of drugs Median (IQR)	Beneficiaries with claim over \$1,000 N (%)	Beneficiaries aged 65+ (%)
Overall	8 (4-13)	94.7%	36.9%
British Columbia	6 (3-10)	97.6%	18.9%
Alberta	7 (3-11)	99.5%	32.5%
Saskatchewan	7 (4-11)	94.9%	20.8%
Manitoba	7 (4-12)	95.9%	21.6%
Ontario	10 (5-15)	93.0%	46.6%
New Brunswick	9 (5-13)	91.6%	33.4%
Prince Edward island	6 (2-12)	73.5%	31.6%
Nova Scotia	8 (4-13)	97.6%	52.7%
Newfoundland and Labrador	10 (6-15)	92.3%	25.8%

IQR: Interquartile range

Supplemental Table S5: Mean and median cost by high drug-cost beneficiaries group, fiscal year 2016

Jurisdiction	Top 1%		Top 5%		Overall	
	Mean Cost (\$)	Median Cost (\$)	Average Cost (\$)	Median Cost (\$)	Average Cost (\$)	Median Cost (\$)
Overall	\$36,429	\$25,615	\$14,567	\$9,140	\$1,566	\$498
Alberta	\$32,545	\$24,482	\$12,502	\$6,785	\$1,329	\$500
British Columbia	\$40,345	\$32,052	\$15,896	\$10,046	\$1,473	\$321
Manitoba	\$62,520	\$47,935	\$25,560	\$17,948	\$2,347	\$578
New Brunswick	\$34,822	\$25,708	\$14,744	\$9,666	\$1,662	\$641
Newfoundland and Labrador	\$28,161	\$21,247	\$10,863	\$6,396	\$1,326	\$548
Nova Scotia	\$30,882	\$23,023	\$11,175	\$5,925	\$1,369	\$583
Ontario	\$36,144	\$24,617	\$14,639	\$9,367	\$1,673	\$580
Prince Edward island	\$18,465	\$15,277	\$6,650	\$3,696	\$632	\$154
Saskatchewan	\$31,319	\$24,022	\$12,253	\$7,135	\$1,106	\$187

Supplemental Figure S1: Lorenz curve of national total spending



Supplemental Figure S2: Lorenz curve of total spending by jurisdiction

